AdAlta Limited is developing pre-clinical and clinical imaging tools for the cell surface receptor CXCR4 in idiopathic pulmonary fibrosis (IPF) patients. IPF is a progressive, degenerative lung disease consisting of recurring inflammation and damage that causes the lung to stiffen, making it hard to breathe. This disease affects approximately 10,000 Australians and more than 500,000 people worldwide with the median length of survival from diagnosis being only 3 to 5 years. Currently available treatments have broad or vague mechanisms of action, multiple side effects and merely slow disease progression.
AdAlta has identified a therapeutic protein called AD-214, that incorporates its i-body technology and demonstrates potent anti-fibrotic properties via a novel mechanism of action. AD-214 is being developed for the treatment of fibrotic diseases including IPF. AD-214 binds with great specificity to its target, the G-protein coupled receptor CXCR4, has been demonstrated effective in pre-clinical studies of fibrosis and could be a first in class/best in class treatment for IPF. This project has successfully labelled or tagged AD-214 so that it can be non-invasively imaged during its evaluation in animal models of fibrosis and in IPF patients. This is the only way that distribution, binding and duration of engagement to the target receptor, CXCR4, can be visualised in the lung.
Pre-clinical imaging has already demonstrated the importance and value of this imaging technique, showing unexpected tissue distribution of an intravenous formulation and pointing towards inhalation being a superior route of administration. The project is now progressing to use these imaging tools to develop an inhaled formulation of AD-214 for future clinical trials and to search for improved intravenous formulations with more appropriate tissue distribution.
BTB Round: One
Project Partners: Alfred Hospital, Monash University, Olivia Newton-John Cancer Research Institute/Austin Health and University of Melbourne
- MTPConnect Grant: $1,100,167
- Industry Contribution: $2,340,167
Duration: February 2020 – June 2022
Contact: AdAlta Enquiries